Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bram De Laere

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2022
Using <sup>68</sup>Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical PracticeChloé S Denis, François Cousin, Bram De Laere, et al.
Oncotarget|March 17, 2016
Evaluation and consequences of heterogeneity in the circulating tumor cell compartmentAnja Brouwer, Bram De Laere, Dieter Peeters, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 31, 2025
Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate CancerChloé S Denis, François Cousin, Bram De Laere, et al.
Plos One|May 7, 2021
Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinomaAnnouck Philippron, Lieven Depypere, Steffi Oeyen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 19, 2024
Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sourcesRenée Bultijnck, Luc De Laere, Rony De Grande, et al.
European Urology Focus|March 23, 2022
Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Prostate Cancer and Prostatic Diseases|November 24, 2020
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancerSteffi Oeyen, Vincent Liégeois, Bram De Laere, et al.
European Urology Focus|May 11, 2026
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Clinical Chemistry|February 10, 2023
Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate CancerMaibritt Nørgaard, Marianne T Bjerre, Jacob Fredsøe, et al.
Elife|July 27, 2022
Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorizationGabriel Renaud, Maibritt Nørgaard, Johan Lindberg, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2022
Using <sup>68</sup>Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical PracticeChloé S Denis, François Cousin, Bram De Laere, et al.
Oncotarget|March 17, 2016
Evaluation and consequences of heterogeneity in the circulating tumor cell compartmentAnja Brouwer, Bram De Laere, Dieter Peeters, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 31, 2025
Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate CancerChloé S Denis, François Cousin, Bram De Laere, et al.
Plos One|May 7, 2021
Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinomaAnnouck Philippron, Lieven Depypere, Steffi Oeyen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 19, 2024
Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sourcesRenée Bultijnck, Luc De Laere, Rony De Grande, et al.
European Urology Focus|March 23, 2022
Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Prostate Cancer and Prostatic Diseases|November 24, 2020
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancerSteffi Oeyen, Vincent Liégeois, Bram De Laere, et al.
European Urology Focus|May 11, 2026
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Clinical Chemistry|February 10, 2023
Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate CancerMaibritt Nørgaard, Marianne T Bjerre, Jacob Fredsøe, et al.
Elife|July 27, 2022
Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorizationGabriel Renaud, Maibritt Nørgaard, Johan Lindberg, et al.
Pageof 4